Market Research Logo

Inclusion Body Myositis (IBM) - Pipeline Review, H2 2015

Inclusion Body Myositis (IBM) - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Inclusion Body Myositis (IBM) - Pipeline Review, H2 2015’, provides an overview of the Inclusion Body Myositis (IBM)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Inclusion Body Myositis (IBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inclusion Body Myositis (IBM) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Inclusion Body Myositis (IBM)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Inclusion Body Myositis (IBM) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Inclusion Body Myositis (IBM) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Inclusion Body Myositis (IBM) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Inclusion Body Myositis (IBM)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Inclusion Body Myositis (IBM) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Inclusion Body Myositis (IBM) Overview
Therapeutics Development
Pipeline Products for Inclusion Body Myositis (IBM) - Overview
Pipeline Products for Inclusion Body Myositis (IBM) - Comparative Analysis
Inclusion Body Myositis (IBM) - Therapeutics under Development by Companies
Inclusion Body Myositis (IBM) - Therapeutics under Investigation by Universities/Institutes
Inclusion Body Myositis (IBM) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Inclusion Body Myositis (IBM) - Products under Development by Companies
Inclusion Body Myositis (IBM) - Products under Investigation by Universities/Institutes
Inclusion Body Myositis (IBM) - Companies Involved in Therapeutics Development
Acceleron Pharma, Inc.
Escala Therapeutics, Inc.
Novartis AG
Ultragenyx Pharmaceutical Inc.
Inclusion Body Myositis (IBM) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AAV1-Foliistatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ACE-083 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
aceneuramic acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bimagrumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DEXM-74 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy for Hereditary Inclusion Body Myopathy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
UX-007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Inclusion Body Myositis (IBM) - Recent Pipeline Updates
Inclusion Body Myositis (IBM) - Dormant Projects
Inclusion Body Myositis (IBM) - Product Development Milestones
Featured News & Press Releases
May 28, 2015: Ultragenyx Announces First Patient Enrolled in Global Phase 3 Study of Aceneuramic Acid (Sialic Acid) Extended Release in GNE Myopathy
Jan 12, 2015: Ultragenyx Announces Intent to File for Conditional Approval in Europe for Sialic Acid Extended-Release Tablets in Hereditary Inclusion Body Myopathy
Oct 13, 2014: Ultragenyx Announces Interim Data From Phase 2 Extension Study of Sialic Acid Extended-Release at International Congress of the World Muscle Society
Apr 30, 2014: Ultragenyx Announces Positive Data From Phase 2 Study of Sialic Acid Extended-Release at Emerging Sciences Session of American Academy of Neurology Annual Meeting
Dec 20, 2013: Ultragenyx Announces Results from Phase 2 Study of Sialic Acid Extended-Release Treatment in Hereditary Inclusion Body Myopathy
Oct 02, 2013: MorphoSys Collaborator to Start Pivotal Study with Bimagrumab
Sep 26, 2013: Ultragenyx Announces Three Abstracts Accepted for Poster Presentation at 18th Annual World Muscle Society Congress
Aug 20, 2013: Novartis receives FDA breakthrough therapy designation for BYM338 (bimagrumab) for sporadic inclusion body myositis (sIBM)
Jul 03, 2013: Ultragenyx Announces a Positive Signal in Interim Data from Phase 2 Study of UX001 in Hereditary Inclusion Body Myopathy
Dec 15, 2011: New Zealand Pharma Obtains FDA Orphan Drug Designation For DEX-M74 To Treat Hereditary Inclusion Body Myopathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Inclusion Body Myositis (IBM), H2 2015
Number of Products under Development for Inclusion Body Myositis (IBM) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Inclusion Body Myositis (IBM) - Pipeline by Acceleron Pharma, Inc., H2 2015
Inclusion Body Myositis (IBM) - Pipeline by Escala Therapeutics, Inc. , H2 2015
Inclusion Body Myositis (IBM) - Pipeline by Nobelpharma Co., Ltd., H2 2015
Inclusion Body Myositis (IBM) - Pipeline by Novartis AG, H2 2015
Inclusion Body Myositis (IBM) - Pipeline by Ultragenyx Pharmaceutical Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Inclusion Body Myositis (IBM) Therapeutics - Recent Pipeline Updates, H2 2015
Inclusion Body Myositis (IBM) - Dormant Projects, H2 2015
List of Figures
Number of Products under Development for Inclusion Body Myositis (IBM), H2 2015
Number of Products under Development for Inclusion Body Myositis (IBM) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report